Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, ...
MannKind has made the decision to discontinue the ICoN-1 Phase 3 clinical trial evaluating nebulized clofazimine inhalation ...
The rise of infections caused by Mgen, C. auris, treatment-resistant E. coli, and more could become future public-health threats, experts say.
Results from PIVOT-PO Phase 3 trial evaluating tebipenem HBr in complicated urinary tract infection (cUTI) presented as IDWeek late-breaker in ...
Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22 ...
The findings of three retrospective studies provide valuable insights into the burden of bronchiectasis across different ...
Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung ...
After assessing data from the first 46 adults with refractory nontuberculous mycobacterial lung disease who completed the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback